H.C. Wainwright lowered the firm’s price target on Prothena (PRTA) to $48 from $84 and keeps a Buy rating on the shares after the Phase 2b PADOVA study results conducted by Roche narrowly missed the statistical significance in the primary endpoint of time to confirmed motor progression.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- RBC sees justification for Prothena rebound after study miss
- Prothena price target lowered to $22 from $26 at BofA
- Prothena price target lowered to $58 from $62 at Oppenheimer
- Capricor, Gilead, Kymera, Praxis among Oppenheimer’s top biotech picks for 2025
- Prothena partner Roche PADOVA study misses primary endpoint